Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Exelixis (EXEL)

Exelixis names Dana Aftab EVP of R&D; CMO Amy Peterson departs

Neutral Impact 3 of 5 leadership Written later

Exelixis said its board appointed Dana T. Aftab, Ph.D., currently Chief Scientific Officer, as Executive Vice President, Research and Development, effective August 29, 2025. The filing also states that Amy C. Peterson, M.D., concluded her service as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer on the same date, and that she is entitled to payments under the company's Change in Control and Severance Benefit Plan. The changes affect the company's senior research and medical leadership, and the filing does not disclose the amount of Dr. Peterson's payments.

Key points

  • Dana T. Aftab, Ph.D., appointed Executive Vice President, Research and Development, effective August 29, 2025
  • Aftab was previously Executive Vice President, Discovery and Translational Research and Chief Scientific Officer
  • Amy C. Peterson, M.D., concluded service as EVP, Product Development and Medical Affairs and Chief Medical Officer effective August 29, 2025
  • Peterson is entitled to payments under the Change in Control and Severance Benefit Plan; amounts not disclosed in the filing

The filing

CompanyExelixis (EXEL)
Form8-K, current report
Filed with the SECAug 29, 2025, 5:10 PM ET
Accession number0000939767-25-000115

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 29, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.